Logo

American Heart Association

  2
  0


Final ID: Sa3038

Disparities in Cardiovascular Multimorbidity and Mortality among Dual Medicare-Medicaid Beneficiaries: A Nationwide Cohort Study of >2 Million Patients

Abstract Body (Do not enter title and authors here): Introduction/Background: Patients dually eligible for Medicare and Medicaid have higher mortality rates and disparate outcomes for acute cardiovascular conditions. However, the association between dual eligibility and cardiovascular multimorbidity and associated mortality is not well-established.
Goals/Aims: To understand differences in cardiovascular disease (CVD) outcomes among patients dually eligible for Medicaid and Medicare.
Methods/Approach: We analyzed Medicare claims data from a 5% random sample of fee-for-service beneficiaries (2010-2019). The exposure was Medicaid dual eligibility. The primary outcomes were the development of incident cardiovascular disease or cardiovascular multimorbidity (defined as >=2 of the following conditions: stroke/TIA, myocardial infarction, atrial fibrillation, heart failure, and ischemic heart disease). The secondary outcome was death. Multistate survival models were used to estimate hazards of progression from no CVD to incident CVD, CVD multimorbidity, and death before and after adjustment for demographics and medical comorbidity burden defined using a 1-year lookback window.
Results/Data: In total, 2,189,382 patients (12.9% dual-eligible for Medicaid) were included. Compared with non-dual eligible beneficiaries, dual-eligible beneficiaries were more likely to have at least one cardiovascular condition at baseline (23.6% vs. 15.0%). Over a median 5 years of follow-up, dual-eligible beneficiaries spent approximately 1 less year alive and free from CVD than non-dual eligible beneficiaries (4.89 years vs. 5.95 years). Dual-eligible beneficiaries were more likely to develop CVD and multimorbidity and had higher mortality rates before and after adjustment (Table 1 and Figure 2).
Conclusions: Dual-eligible beneficiaries had higher rates of incident CVD, cardiovascular multimorbidity and associated mortality, illuminating the critical need for primary and secondary prevention of CVD in this vulnerable population.
  • Lusk, Jay  ( Duke University , Durham , North Carolina , United States )
  • Kalapura, Cheryl  ( Duke University , Durham , North Carolina , United States )
  • Mentz, Robert  ( Duke Clinical Research Institute , Durham , North Carolina , United States )
  • Greene, Stephen  ( Duke Clinical Research Institute , Durham , North Carolina , United States )
  • Hammill, Bradley  ( Duke University School of Medicine , Chapel Hill , North Carolina , United States )
  • Mac Grory, Brian  ( Duke University , Durham , North Carolina , United States )
  • Li, Fan  ( Duke University , Durham , North Carolina , United States )
  • Xian, Ying  ( UTSW , Dallas , Texas , United States )
  • Obrien, Emily  ( Duke University , Durham , North Carolina , United States )
  • Author Disclosures:
    Jay Lusk: DO NOT have relevant financial relationships | Cheryl Kalapura: DO NOT have relevant financial relationships | Robert Mentz: DO have relevant financial relationships ; Researcher:AstraZeneca:Active (exists now) ; Researcher:American Regent:Active (exists now) ; Researcher:Bayer/Merck:Active (exists now) ; Researcher:BI/Lilly:Active (exists now) ; Researcher:Novartis:Active (exists now) | Stephen Greene: DO have relevant financial relationships ; Consultant:AstraZeneca:Active (exists now) ; Consultant:Corcept:Past (completed) ; Consultant:Otsuka:Active (exists now) ; Consultant:Lilly:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) ; Consultant:Merck:Active (exists now) ; Consultant:Roche Diagnostics:Active (exists now) ; Consultant:Lexicon:Active (exists now) ; Consultant:Boehringer Ingelheim:Active (exists now) ; Consultant:Cytokinetics:Past (completed) ; Consultant:Bayer:Active (exists now) | Bradley Hammill: DO NOT have relevant financial relationships | Brian Mac Grory: No Answer | Fan Li: DO NOT have relevant financial relationships | Ying Xian: DO NOT have relevant financial relationships | Emily Obrien: DO have relevant financial relationships ; Research Funding (PI or named investigator):Pfizer:Active (exists now) ; Research Funding (PI or named investigator):BMS:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Breaking Barriers: Addressing Health Disparities for Improved Outcomes

Saturday, 11/16/2024 , 10:30AM - 11:30AM

Abstract Poster Session

More abstracts on this topic:
The contribution of morbidity clusters in late life to stroke incidence and severity: The Atherosclerosis Risk in Communities (ARIC) study

Egle Marco, Groechel Renee, Johansen Michelle, Kucharska-newton Anna, Gottesman Rebecca, Koton Silvia

Drivers of Disparities in Stroke Outcomes by Neighborhood Socioeconomic Status: A Causal Mediation Analysis

Stulberg Eric, Miller Robert, Hartman Nicholas, De Havenon Adam, Lisabeth Lynda

You have to be authorized to contact abstract author. Please, Login
Not Available